Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

Novavax Inc (NVAX) outlines its strategic focus on partnerships and pipeline expansion while navigating revenue fluctuations ...

Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a ...

Our fair value estimate is 8.2% lower than Novavax's analyst price target of US$16.43 How far off is Novavax, Inc. (NASDAQ:NVAX) from its intrinsic value? Using the most recent financial data, we'll ...

Novavax's net loss was $81 million for the quarter ended December 31, compared with a net loss of $178.3 million a year ago.

Transitioned lead commercial responsibility of Nuvaxovid COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in ...

Novavax has significantly reduced its net loss in the fourth quarter of 2024 to $81.03 million ($0.51 per share), a ...

Novavax in May had signed a deal worth at least $1.2 billion with Sanofi to hand over the rights to sell its vaccines in several markets, including the United States and Europe, in exchange for a ...

Novavax Inc. shares climbed 2% on Wednesday and extended gains in after-hours trading, as retail investors maintained a ...

Novavax Inc. (NVAX) shares climbed over 1% in after-hours trading Thursday as the vaccine maker's revenue outlook and ...